Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA federal affairs

Executive Summary

Former PhRMA Senior VP-Federal Affairs David Mohler will join the Washington, D.C. offices of law firm Foley Hoag as counsel to the Life Sciences and Government Strategies practices effective April 3. Mohler, who had worked in federal affairs at PhRMA between stints at Upjohn and Merck, returned to PhRMA in 2001 (1"The Pink Sheet" May 14, 2001, p. 36). After resigning on Jan. 3, Mohler was replaced by Alan Gilbert, who joined the association in May 2005 to be groomed for the position. Gilbert, a Capitol Hill veteran, most recently worked in the White House as special assistant to the President for health policy...

You may also be interested in...


David Mohler returns to Pharmaceutical Research & Manufacturers of America as deputy VP-federal affairs. Mohler previously served as a legislative counsel for the association, and was most recently in Merck's D.C. office. Former U.S. Chamber of Commerce health lobbyist Missy Jenkins is joining PhRMA as senior director-federal affairs. Jenkins was previously a staffer to former Rep. Gingrich (R-Ga.) and Sen. Simpson (R-Wyo.). Mohler and Jenkins will report to VP-Federal Affairs & Law Rodger Currie

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts